Notably, over 50% of the participants included in this meta‐analysis were from the EMPA‐REG OUTCOME study.33 A recent meta‐analysis that included 82 SGLT‐2 trials and 1968 major cardiovascular events further confirmed that SGLT2 inhibitors were protective against major cardiovascular events, heart failure, as well as all‐cause mortality.34 When interpreting the effects of SGLT‐2 inhibitors on cardiovascular outcomes it is important to consider the beneficial effects of concurrent antihypertensive therapies on these outcomes. Here, SLC5A2 is linked to heart failure.